Major Depressive Disorder
Conditions
Interventions
test group :Morinda officinalis oligosaccharide capsules combined with probiotics
placebo group:Morinda officinalis oligosaccharide capsules combined with placebo
Sponsors
Beijing Anding Hospital affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for major depressive disorder in the American Diagnostic and Statistical Manual of Mental Disorders 5th Edition (DSM-5), with either first episode or relapse, without psychotic symptoms; 2. Aged 18 to 65 years, male or female; 3. 14 = 5; 5. At least 3 symptom scores between 4 and 6 on the GSRS scale (moderate to severe discomfort); 6. The subjects can understand and comply with the research requirements and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Subjects who are currently or previously diagnosed with other disorders than major depressive disorder according to the MINI; 2. Current or past substance abuse; 3. Subjects who have received any surgical treatment, vagus nerve stimulation, deep brain stimulation treatment or stem cell treatment for depression; 4. Patients currently undergoing MECT and other physical therapy; 5. The patient currently has a serious risk of suicide, and the HAMD-17 suicide risk item is >= 3; 6. Subjects with unstable physical diseases that require medical or surgical treatment; 7. Suffering from inflammation, tumor, autoimmune disease, diabetes; 8. Gastrointestinal organic diseases with gastrointestinal inflammation, infection, tumor and other structural abnormalities; 9. Use of any antibiotics, probiotic products and laxatives within 1 month before entering the study; 10. Those who have been allergic or ineffective when taking Morinda officinalis oligosaccharide capsules in the past; 11. Patients who are using antipsychotics, antidepressants and mood stabilizers with less than 5 half-lives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HAMD total score deduction value; | — |
Secondary
| Measure | Time frame |
|---|---|
| difference in efficiency;Changes in the total score on the GAD-7 scale;Changes in blood and stool indexes;Changes in the total score of GSRS and CAS;Early efficiency; | — |
Countries
China
Contacts
Public ContactWang Gang
Beijing Anding Hospital affiliated to Capital Medical University
Outcome results
None listed